Finance

Lists
214390:KRX
Kyongbo Pharmaceutical Co Ltd
₩5 350,00
+1,90%
(+100,00) 1D
19 Okt., 15:30:30 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 214390...
Open
₩5 250
High
₩5 420
Low
₩5 250
Mkt. cap
127,90 mjd
Avg. vol.
24,96 k
Volume
15,49 k
Dividend
0,93%
Quarterly dividend
â‚©12
Ex-dividend date
29 Des. 2025
P/E ratio
25,41
52-wk high
₩9 300
52-wk low
₩4 700
EPS
â‚©211
Shares outstanding
23,91 m
No. of employees
588
Open
₩5 250
High
₩5 420
Low
₩5 250
Mkt. cap
127,90 mjd
Avg. vol.
24,96 k
Volume
15,49 k
Dividend
0,93%
Quarterly dividend
â‚©12
Ex-dividend date
29 Des. 2025
P/E ratio
25,41
52-wk high
₩9 300
52-wk low
₩4 700
EPS
â‚©211
Shares outstanding
23,91 m
No. of employees
588
News stories
From web sources and news partners
About Kyongbo Pharmaceutical Co Ltd
CEOKim Tae-young
Employees588
Founded31 Mrt. 1987
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
66,99 mjd
71,22 mjd
66,13 mjd
75,22 mjd
Cost of goods sold
42,39 mjd
44,46 mjd
38,69 mjd
46,54 mjd
Cost of revenue
42,39 mjd
44,46 mjd
38,69 mjd
46,54 mjd
Research and development expenses
4,46 mjd
4,50 mjd
4,92 mjd
4,99 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,88 mjd
20,67 mjd
20,97 mjd
21,99 mjd
Operating expense
24,12 mjd
26,24 mjd
26,73 mjd
27,75 mjd
Total operating expenses
66,51 mjd
70,70 mjd
65,41 mjd
74,29 mjd
Operating income
474,48 m
515,50 m
712,77 m
930,33 m
Other non operating income
-1,10 mjd
2,51 mjd
-1,44 mjd
3,36 mjd
EBT including unusual items
3,44 mjd
-995,05 m
-741,91 m
4,27 mjd
EBT excluding unusual items
3,44 mjd
-857,95 m
-741,91 m
4,27 mjd
Income tax expense
412,26 m
-562,40 m
-212,24 m
1,29 mjd
Effective tax rate
11,97%
56,52%
28,61%
30,33%
Other operating expenses
194,62 m
276,72 m
190,08 m
187,64 m
Net income
3,03 mjd
-432,65 m
-529,67 m
2,97 mjd
Net profit margin
4,53%
-0,61%
-0,80%
3,95%
Earnings per share
-
-
-
-
Interest and investment income
-
41,30 m
-
-
Interest expense
-
-4,29 mjd
-
-
Net interest expenses
-
-4,25 mjd
-
-
Depreciation and amortization charges
377,69 m
385,22 m
323,46 m
327,67 m
EBITDA
3,86 mjd
3,95 mjd
4,29 mjd
4,64 mjd
Gain or loss from assets sale
-6,40 m
10,00 k
-5,48 m
13,90 m
AI content may include mistakes. Learn more
Google-programme